Dr. Kuzel on Immunotherapy as a Targeted Approach to Cancer

Video

In Partnership With:

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Timothy M. Kuzel, MD, FACP, chief, Hematology Oncology and Cell Therapy, Rush University Medical Center, discusses the use of immunotherapy as a targeted approach to treating cancer.

Over the past few years, many new approaches and agents have been developed to treat patients with a variety of cancers, including kidney cancer, melanoma, bladder cancer, and more, according to Kuzel. Compared with previous years, Kuzel believes this year has seen fewer novel drugs and big trials with paradigm shifts; rather, there are more data refining the way these drugs should be used. Kuzel has seen studies examining genetic sequencing and mutations in certain tumors, which has an impact on the response to immunotherapy.

The medical community is starting to think of immunotherapy as a targeted approach to cancer rather than a broad therapeutic approach, according to Kuzel.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD